Back to top
more

ChromaDex (CDXC)

(Delayed Data from NSDQ)

$6.77 USD

6.77
988,022

-0.22 (-3.15%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $6.75 -0.02 (-0.30%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 8.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of -12.50% and 8.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 27.27% and 3.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aeglea (AGLE) delivered earnings and revenue surprises of 3.12% and 18.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of -30.00% and 0.76%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 11.11% and 7.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of -33.33% and -10.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in ChromaDex (CDXC) Stock?

by Zacks Equity Research

Investors need to pay close attention to ChromaDex (CDXC) stock based on the movements in the options market lately.

ChromaDex (CDXC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 9.09% and 0.31%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Surges 12%: Is This an Indication of Further Gains?

by Zacks Equity Research

ChromaDex (CDXC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) in Focus: Stock Moves 5.6% Higher

by Zacks Equity Research

ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 36.36% and -0.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 45.45% and 12.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 18.18% and 4.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Jumps: Stock Rises 7.7%

by Zacks Equity Research

ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

ChromaDex (CDXC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 8.33% and 2.23%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.